On the heels of a shortage of nirsevimab for infant respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) prevention, a new tool may help identify newborns at highest risk for developing serious RSV LRTI, according to new research.
Read more https://www.sciencedaily.com/releases/2024/05/240521204336.htm